Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Revvity Inc (RVTY) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance

Revvity IncTrade
iShares Broad USD Investment Grade Corporate BondTrade

Price performance (Past 24H)

Key statistics

Revvity Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Revvity Inc trades at $117.6 (market cap $12.91B), while iShares Broad USD Investment Grade Corporate Bond trades at $50.25. The key difference: Revvity Inc pays a 0.24% dividend while iShares Broad USD Investment Grade Corporate Bond pays none, and Revvity Inc is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.

RVTYUSIG
Market Cap
$12.91B
Sector
TechnologyFixed Income
52-Week High
$117.75$52.69
52-Week Low
$82.26$50.18
Enterprise Value
$15.23B
Dividend Yield
0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Revvity Inc

RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.

The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.

iShares Broad USD Investment Grade Corporate Bond

USIG trades at $50.26, up 0.16% on the day, with a bearish technical signal from moving averages. Recent corporate actions include dividend payments, with the latest being $0.21 per share. The company's subsidiaries maintained credit ratings following a transaction with Tiptree Inc., as noted by AM Best on July 30, 2026.

The outlook is mixed, with technical indicators signaling caution, but institutional interest is present, as Bank of New York Mellon Corp increased its stake. Key risks include market volatility and execution of corporate strategies. The stock presents opportunities for income-focused investors due to dividends, but requires monitoring of fundamental developments.

Returns comparison

Trailing returns across standard periods

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY

About iShares Broad USD Investment Grade Corporate Bond

USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.

Read more on USIG